Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1b study is to assess the safety and maximum tolerated dose (MTD)
of Decitabine in combination with Gemcitabine among previously treated patients diagnosed
with advanced pancreatic adenocarcinoma or sarcoma (soft tissue and bone).
Phase:
Phase 1
Details
Lead Sponsor:
Laith Abushahin Varun Monga, MD
Collaborators:
Holden Comprehensive Cancer Center University of Iowa